Source comparison
Melanotan-2 for Appetite Suppression: Peptide Comparison
The following table compares Melanotan-2 to other peptides commonly investigated for appetite regulation and metabolic modulation in research settings. Melanotan-2 MC3R/MC4R agonist (central hypothalamic signaling) 48–72 hours 0.5–1.5mg daily SC ~33 min (effec
This comparison does not assign a generated winner or score.
- The following table compares Melanotan-2 to other peptides commonly investigated for appetite regulation and metabolic modulation in research settings.
- Melanotan-2
- MC3R/MC4R agonist (central hypothalamic signaling)
- 48–72 hours
- 0.5–1.5mg daily SC
- ~33 min (effects last 8–12 hours)
- Rapid onset, central mechanism, no GI motility changes. Best for leptin-resistant models
- Semaglutide
- GLP-1 receptor agonist (peripheral incretin and gastric emptying)
- 4–8 weeks (dose-dependent)
- 0.25–2.4mg weekly SC
- ~7 days
- Slow titration required, strong clinical evidence, high nausea incidence during escalation
- Tirzepatide
- Dual GIP/GLP-1 receptor agonist
- 4–8 weeks
- 2.5–15mg weekly SC
- ~5 days
- Superior weight loss vs semaglutide in trials, requires titration, GI side effects common
- Tesofensine
- Triple monoamine reuptake inhibitor (dopamine, norepinephrine, serotonin)
- 7–14 days
- 0.25–1mg daily oral
- ~8 days
- CNS stimulant mechanism, cardiovascular monitoring required, not melanocortin-mediated
- AOD9604
- Modified C-terminal fragment of hGH (lipolytic, no appetite effect)
- Not applicable
- 300–600mcg daily SC
- ~2 hours
- No direct appetite suppression. Lipolysis only, often stacked with appetite modulators
- 5-Amino-1MQ
- NNMT inhibitor (increases NAD+ and metabolic rate)
- Minimal to none
- 50–100mg daily oral
- Unknown
- Metabolic rate modulation without central appetite suppression. Different pathway